是否加量:两项两分次SABR试验针对局限性前列腺癌的汇总分析
汇总两项2期试验共60例低至中危前列腺癌患者,比较两分次SABR±优势前列腺内病灶(DIL)加量的疗效与毒性。两分次SABR加DIL加量后4年PSA应答率与生化失败率相似,但急性及晚期≥1级尿急和晚期泌尿生活质量改变在加量组更常见。
要点
- 两分次SABR加DIL加量后4年PSA应答率57% vs 63%(P=0.7),4年累计生化失败0% vs 8.3%(P=0.1)。
- 加量组急性≥1级尿急0% vs 47%(P<.001)、晚期10% vs 67%(P<.001),均不利于加量组。
- 晚期泌尿生活质量评分出现最小临床重要改变的比例21% vs 50%(P=.03),加量组更高。
核心结论
- 两分次前列腺SABR加DIL加量后中期疗效(4年PSA应答率和生化失败)相似,但对晚期泌尿生活质量有影响。
研究设计与样本
- 汇总两项2期试验(2STAR NCT02031328和2SMART NCT03588819)共60例低至中危前列腺癌患者,每项试验30例。
- 2STAR试验前列腺照射26 Gy(2 Gy分次等效剂量105.4 Gy);2SMART试验前列腺照射26 Gy并对MRI定义的DIL加量至32 Gy(2 Gy分次等效剂量156.4 Gy)。
- 报告结局包括4年PSA应答(<0.4 ng/mL)、生化失败、急性和晚期毒性及生活质量。
主要发现
- 2SMART试验中DIL D99%中位剂量为32.3 Gy;2STAR中位随访72.7个月(范围69.1-75),2SMART中位随访43.6个月(范围38.7-49.5)。
- 4年PSA应答率2STAR为57%(17/30)vs 2SMART为63%(15/24)(P=0.7)。
- 4年累计生化失败2STAR为0% vs 2SMART为8.3%(P=0.1);2STAR的6年生化失败为3.5%。
- 泌尿生殖毒性:急性≥1级尿急2STAR为0% vs 2SMART为47%(P<.001),晚期为10% vs 67%(P<.001),均有利于2STAR。
- 晚期泌尿生活质量评分出现最小临床重要改变的比例2STAR为21% vs 2SMART为50%(P=.03);急性期无差异,两组急性和晚期胃肠道及性功能毒性和生活质量无显著差异。
局限性
- 2STAR中位随访72.7个月(范围69.1-75),2SMART中位随访43.6个月(范围38.7-49.5)。
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Focal boost to dominant intraprostatic lesion (DIL) is an approach for dose escalation in prostate radiation therapy. In this study, we aimed to report the outcomes of 2-fraction SABR ± DIL boost. METHODS AND MATERIALS: We included 60 patients with low- to intermediate-risk prostate cancer enrolled in 2 phase 2 trials (30 patients in each trial). In the 2STAR trial (NCT02031328), 26 Gy (equivalent dose in 2-Gy fractions = 105.4 Gy) was delivered to the prostate. In the 2SMART trial (NCT03588819), 26 Gy was delivered to the prostate, with up to 32 Gy boost to magnetic resonance imaging-defined DIL (equivalent dose in 2-Gy fractions = 156.4 Gy). The reported outcomes included prostate-specific antigen (PSA) response (ie, <0.4 ng/mL) at 4 years (4yrPSARR), biochemical failure (BF), acute and late toxicities, and quality of life (QOL). RESULTS: In 2SMART, median DIL D99% of 32.3 Gy was delivered. Median follow-up was 72.7 months (range, 69.1-75.) in 2STAR and 43.6 months (range, 38.7-49.5) in 2SMART. The 4yrPSARR was 57% (17/30) in 2STAR and 63% (15/24) in 2SMART (P = 0.7). The 4-year cumulative BF was 0% in 2STAR and 8.3% in 2SMART (P = 0.1). The 6-year BF in 2STAR was 3.5%. For genitourinary toxicities, there were differences in grade ≥1 urinary urgency in the acute (0% vs 47%; P < .001) and late settings (10% vs 67%; P < .001) favoring 2STAR. For urinary QOL, no difference was observed in the acute setting, but lower proportion in 2STAR had minimal clinically important changes in urinary QOL score in the late setting (21% vs 50%; P = .03). There were no significant differences in gastrointestinal and sexual toxicities and QOL in both acute and late settings between the 2 trials. CONCLUSIONS: This study presents the first prospective data comparing 2-fraction prostate SABR ± DIL boost. The addition of DIL boost resulted in similar medium-term efficacy (in 4yrPSARR and BF), with impact on late urinary QOL outcomes.
引用
- Ong WL, Cheung P, Chung H, et al. To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37419394. doi:10.1016/j.ijrobp.2023.06.250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。